抗GM-CSF单抗Gimsilumab治疗COVID-19肺炎的随机双盲安慰剂对照试验
BREATHE试验在美国21个中心随机双盲纳入225例住院COVID-19肺炎伴炎症标志物升高和低氧血症患者,比较Gimsilumab与安慰剂。第43天全因死亡率分别为28.3%和23.2%(校正差异5%,95%CI -6至17,P=0.377),主要及关键次要终点均无显著差异,研究因无效提前终止。
要点
- Gimsilumab未改善COVID-19肺炎患者第43天全因死亡率。
- 无呼吸机生存率、无呼吸机天数及出院时间等关键次要终点均无显著差异。
- 不良事件在治疗组间总体均衡,但研究因无效提前终止。
核心结论
- Gimsilumab未能改善COVID-19肺炎伴全身炎症证据患者的死亡率或其他关键临床结局。
- 抗GM-CSF治疗在COVID-19中的效用仍不明确。
研究设计与样本
- 24周随机、双盲、安慰剂对照试验(BREATHE),在美国21个地点开展。
- 计划入组270例,实际随机并给药225例,按1:1分配接受两剂静脉Gimsilumab或安慰剂,间隔1周。
- 主要终点为第43天全因死亡率;关键次要终点包括无呼吸机生存率、无呼吸机天数和出院时间。
- 基于中期分析因无效提前终止入组。
主要发现
- 第43天全因死亡率:Gimsilumab组28.3%,安慰剂组23.2%(校正差异=5% vs 安慰剂;95%CI [-6至17];P=0.377)。
- 24周总死亡率在各治疗组间相似。
- 关键次要终点组间无显著差异。
- 尽管背景使用皮质类固醇和抗凝药比例高,不良事件在治疗组间总体均衡。
临床怎么用
- 不推荐对COVID-19肺炎伴全身炎症证据的住院患者使用Gimsilumab以改善死亡率。
- 抗GM-CSF治疗COVID-19的临床价值尚需进一步研究明确。
局限性
- 研究因无效提前终止,实际样本量225例低于计划270例。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: GM-CSF (granulocyte-macrophage colony-stimulating factor) has emerged as a promising target against the hyperactive host immune response associated with coronavirus disease (COVID-19). Objectives: We sought to investigate the efficacy and safety of gimsilumab, an anti-GM-CSF monoclonal antibody, for the treatment of hospitalized patients with elevated inflammatory markers and hypoxemia secondary to COVID-19. Methods: We conducted a 24-week randomized, double-blind, placebo-controlled trial, BREATHE (Better Respiratory Education and Treatment Help Empower), at 21 locations in the United States. Patients were randomized 1:1 to receive two doses of intravenous gimsilumab or placebo 1 week apart. The primary endpoint was all-cause mortality rate at Day 43. Key secondary outcomes were ventilator-free survival rate, ventilator-free days, and time to hospital discharge. Enrollment was halted early for futility based on an interim analysis. Measurements and Main Results: Of the planned 270 patients, 225 were randomized and dosed; 44.9% of patients were Hispanic or Latino. The gimsilumab and placebo groups experienced an all-cause mortality rate at Day 43 of 28.3% and 23.2%, respectively (adjusted difference = 5% vs. placebo; 95% confidence interval [-6 to 17]; P = 0.377). Overall mortality rates at 24 weeks were similar across the treatment arms. The key secondary endpoints demonstrated no significant differences between groups. Despite the high background use of corticosteroids and anticoagulants, adverse events were generally balanced between treatment groups. Conclusions: Gimsilumab did not improve mortality or other key clinical outcomes in patients with COVID-19 pneumonia and evidence of systemic inflammation. The utility of anti-GM-CSF therapy for COVID-19 remains unclear. Clinical trial registered with www.clinicaltrials.gov (NCT04351243).
引用
- Criner GJ, Lang FM, Gottlieb RL, et al. Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial. Am J Respir Crit Care Med. 2022. PMID: 35290169. doi:10.1164/rccm.202108-1859OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。